Introduction
============

The metabolism of malignant tumors is generally explained by the Warburg effect theory, which describes the metabolic shift from mitochondrial oxidative phosphorylation (OXPHOS) to glycolysis in tumors \[[@B1]\]. Breast cancer is known to be heterogeneous, and the interaction between tumor cells and adjacent stroma is expected to have significant roles in tumor growth and progression. This kind of complex interaction may also exist in the metabolic processes of the tumor. Previous studies suggest a unique metabolic interaction between tumor cells and the stroma of breast cancer, known as the *reverse Warburg effect theory*\[[@B2]-[@B5]\]. According to this theory, reactive oxygen species (ROS), such as nitric oxide (NO), generated by tumor cells bring oxidative stress to the stromal cells, leading to mitochondrial dysfunction, autophagy (mitophagy) and increased aerobic glycolysis through hypoxia-inducible factor 1α (HIF-1α) and nuclear factor κB (NF-κB). Lactate generated by stromal cell glycolysis enters tumor cells and promotes tumor cell growth and survival through efficient generation of ATP by OXPHOS in the mitochondria. Cancer-associated fibroblasts (CAFs), stromal cells with loss of caveolin-1 expression, have been implicated in this interaction in breast cancer because loss of caveolin-1 results from increased proteolysis by autophagy \[[@B3],[@B5]-[@B7]\]. In addition to the reverse Warburg effect theory, it has been reported that certain types of tumor cells generate ATP through glycolysis as well as OXPHOS, which suggests various features of tumor metabolism \[[@B8],[@B9]\]. Proteins involved in metabolism, mitochondrial function and autophagy may be differentially expressed in both tumor and stromal cells according to the aforementioned theories. These differences are summarized in Table  [1](#T1){ref-type="table"}.

###### 

**Comparison of metabolism type, mitochondrial status and autophagy status between the Warburg effect theory and reverse Warburg effect theory**^**a**^

                         **Warburg effect theory**   **Reverse Warburg effect theory**   
  ---------------------- --------------------------- ----------------------------------- ---------------
  Metabolism             Glycolysis                  OXPHOS                              Glycolysis
  Mitochondrial status   Dysfunctional               Functional                          Dysfunctional
  Autophagy status       Not included                Not activated                       Activated

^a^OXPHOS, oxidative phosphorylation.

Because breast cancer is heterogeneous with respect to clinical, histopathological and molecular features, several subclassifications have been investigated to stratify tumors with similar characteristics. Gene expression profiles have enabled molecular classification of tumors into luminal A, luminal B, HER2, normal breast-like and basal-like types \[[@B10]-[@B12]\]. Studies have also revealed differences in histological and clinical manifestation between different molecular subtypes, such as therapeutic response and prognosis. We hypothesized that the metabolic interaction between tumor cells and stroma may differ according to the molecular subtypes of breast cancer. Because there are limited studies regarding this question, the aim of our present study was designed to investigate the differential expression of markers for metabolic, mitochondrial and autophagy status in different molecular subtypes of breast cancer.

Methods
=======

Patient selection
-----------------

Patients diagnosed with invasive breast cancer treated by surgical resection during the period from January 2002 to December 2006 were included in this study. Patients who received preoperative neoadjuvant chemotherapy or hormonal treatment were excluded. This study was approved by the Institutional Review Board (IRB) of Yonsei University Severance Hospital. The IRB exempted the informed consent from patients. A breast pathologist (JSK) retrospectively reviewed the histology of all cases using hematoxylin and eosin (H&E)-stained slides. The histological grade was assessed using the Nottingham grading system \[[@B13]\]. Clinicopathologic parameters evaluated in each case included patient age at initial diagnosis, lymph node metastasis, tumor recurrence, distant metastasis and patient survival.

Tissue microarray
-----------------

On H&E-stained slides of tumors, a representative area was selected and the corresponding spot was marked on the surface of the paraffin block. Using a biopsy needle, the selected area was punched out and a 3-mm tissue core was placed into a 6 × 5 recipient block. Tissue from the invasive tumor was then extracted. More than two tissue cores were extracted to minimize extraction bias. Each tissue core was assigned a unique tissue microarray (TMA) location number that was linked to a database containing other clinicopathologic data.

Immunohistochemistry
--------------------

The antibodies used for immunohistochemistry (IHC) in this study are shown in Table  [2](#T2){ref-type="table"}. Formalin-fixed, paraffin-embedded (FFPE) tissue sections from the TMA were prepared for IHC. Briefly, 5-μm-thick sections were obtained using a microtome, transferred into adhesive slides and dried at 62°C for 30 min. After incubation with primary antibodies, immunodetection was performed with biotinylated anti-mouse immunoglobulin, followed by peroxidase-labeled streptavidin using a labeled streptavidin biotin kit with 3,3′-diaminobenzidine chromogen as the substrate. The primary antibody incubation step was omitted in the negative control. A positive control was included for each experiment: glucose transporter 1 (Glut-1): esophageal carcinoma; carbonic anhydrase IX (CAIX): renal carcinoma; monocarboxylate transporter 4 (MCT4): BCL2/adenovirus E1B 19-kDa interacting protein 3 (BNIP3), kidney tissue; Beclin-1: breast tissue; microtubule-associated protein 1 light chain 3α (LC3A): brain tissue; microtubule-associated protein 1 light chain 3β (LC3B): brain tissue, p62: spleen tissue; ATP synthase: heart tissue; and glutaminase: liver tissue. Slides were counterstained with Harris hematoxylin.

###### 

**Source, clone and dilution of antibodies used in this study**^**a**^

  **Antibody**                       **Clone**     **Dilution**  **Company**
  ---------------------------------- ------------ -------------- -----------------------------------------------
  Molecular subtype-related                                       
   ER                                SP1              1:100      Thermo Scientific, Waltham, MA, USA
   PR                                PgR               1:50      Dako Denmark AS, Glostrup, Denmark
   HER2                              Polyclonal      1:1,500     Dako Denmark AS, Glostrup, Denmark
   Ki-67                             MIB-1            1:150      Dako Denmark AS, Glostrup, Denmark
  Glycolysis-related                                              
   Glut-1                            SPM498           1:200      Abcam, Cambridge, UK
   CAIX                              Polyclonal       1:100      Abcam, Cambridge, UK
   MCT4                              Polyclonal       1:100      Santa Cruz Biotechnology, Santa Cruz, CA, USA
  Mitochondrial status-related                                    
   BNIP3                             Ana40            1:100      Abcam, Cambridge, UK
  Mitochondrial metabolism-related                                
   ATP synthase                      15H4C4           1:100      Abcam, Cambridge, UK
   Glutaminase                       Polyclonal       1:100      Abcam, Cambridge, UK
  Autophagy-related                                               
   Beclin-1                          Polyclonal       1:100      Abcam, Cambridge, UK
   LC3A                              EP1528Y          1:100      Abcam, Cambridge, UK
   LC3B                              Polyclonal       1:100      Abcam, Cambridge, UK
   p62                               SQSTM1           1:100      Abcam, Cambridge, UK

^a^BNIP3, BCL2/adenovirus E1B 19-kDa interacting protein 3; CAIX, carbonic anhydrase IX; ER, estrogen receptor; Glut-1, glucose transporter 1; LC3A, microtubule-associated protein 1 light chain 3α; LC3B, microtubule-associated protein 1 light chain 3β; MCT4, monocarboxylate transporter 4; PR, progesterone receptor.

Interpretation of immunohistochemical staining
----------------------------------------------

All immunohistochemical markers were assessed by light microscopy. Pathologic parameters such as ER, PR and HER2 expression were obtained from each patient's pathologic report. A cutoff value of 1% or more positively stained nuclei was used to define ER and PR positivity \[[@B14]\]. HER2 staining was analyzed according to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines using the following categories: 0 = no immunostaining; 1+ = weak, incomplete membranous staining, less than 10% of tumor cells; 2+ = complete membranous staining, either uniform or weak in at least 10% of tumor cells; and 3+ = uniform intense membranous staining in at least 30% of tumor cells \[[@B15]\]. HER2 immunostaining was considered positive when strong (3+) membranous staining was observed, whereas cases with 0 to 1+ were regarded as negative. Cases showing 2+ HER2 expression were evaluated for HER2 amplification by fluorescence *in situ* hybridization (FISH).

Glut-1, CAIX, BNIP3, MCT4, Beclin-1, LC3A, LC3B and p62 immunohistochemical staining was evaluated on the basis of the proportion of stained cells and immunostaining intensity. The proportion of stained cells was graded 0 (negative), 1 (less than 30% positive) or 2 (more than 30% positive). Immunostaining intensity was graded as 0 (negative), 1 (weak), 2 (moderate) or 3 (strong). The scores for the proportion of stained cells and staining intensity were multiplied to provide a total score: negative (0 or 1) or positive (2 through 6). Ki-67 labeling indices (LIs) were scored by counting the number of positively stained nuclei and expressed as a percentage of total tumor cells.

Fluorescence *in situ* hybridization analysis
---------------------------------------------

Before FISH analysis, invasive tumors were examined on H&E-stained slides. FISH was subsequently performed on the confirmed tumor. FISH was performed using the PathVysion HER-2 DNA Probe Kit (Abbott Molecular, Abbott Park, IL, USA) according to the manufacturer's instructions. *HER2* gene copy number on the slides was evaluated using an epifluorescence microscope (Olympus, Tokyo, Japan). At least 60 tumor cell nuclei in three separate regions were investigated for *HER2* and chromosome 17 signals. *HER2* gene amplification was determined according to the ASCO/CAP guidelines \[[@B15]\]. An absolute *HER2* gene copy number lower than 4 or a *HER2* gene/chromosome 17 (chr17) copy number ratio (HER2/chr17 ratio) less than 1.8 was considered *HER2*-negative. An absolute *HER2* copy number between 4 and 6 or a HER2/chr17 ratio between 1.8 and 2.2 was considered *HER2*-equivocal. An absolute *HER2* copy number greater than 6 or a HER2/chr17 ratio higher than 2.2 was considered *HER2*-positive.

Tumor phenotype classification
------------------------------

In this study, we classified breast cancer phenotypes according to the IHC results for ER, PR, HER2 and Ki-67 LI. FISH results for HER2 were as follows \[[@B16]\]: luminal A type: ER- and/or PR-positive, HER2-negative Ki-67 LI less than 14%; luminal B type: (HER2-negative) ER- and/or PR-positive, HER2-negative and Ki-67 LI greater than or equal to 14% and (HER2-positive) ER- and/or PR-positive and HER2 overexpressed and/or amplified; HER2 type: ER- and PR-negative and HER2 overexpressed and/or amplified; TNBC type: ER-, PR- and HER2-negative.

Classification of tumor metabolic subtypes
------------------------------------------

We also classified cases based on the results of immunohistochemical staining for metabolism-related proteins as follows: glycolysis type: Glut-1- and/or CAIX-positive; nonglycolysis type: Glut-1- and CAIX-negative; dysfunctional mitochondrial type: BNIP3-positive \[[@B17],[@B18]\]; functional mitochondrial type: BNIP3-negative; activated autophagy type: positive for two or more markers from among Beclin-1, LC3A, LC3B and p62; and nonactivated autophagy type: positive for less than two markers from among Beclin-1, LC3A, LC3B and p62. We further classified the metabolic phenotypes of breast cancer as follows: Warburg type: tumor (glycolysis type), stroma (nonglycolysis type); reverse Warburg type: tumor (nonglycolysis type), stroma (glycolysis type); mixed type: tumor (glycolysis type), stroma (glycolysis); and null type: tumor (nonglycolysis type), stroma (non-glycolysis type).

Laser microdissection and protein extraction from formalin-fixed, paraffin-embedded tissues
-------------------------------------------------------------------------------------------

To acquire tumors and tumor stroma, laser microdissection was performed with hematoxylin-stained, uncovered slides generated with FFPE blocks (LMD 6500; Leica, Wetzlar, Germany). Five cases per molecular subtype of breast cancer were microdissected. Protein extraction from microdissected FFPE tissues was performed using the Qproteome FFPE Tissue Kit (QIAGEN, Hilden, Germany). Briefly, microdissected FFPE tissues were deparaffinized in xylene and rehydrated in a graded series of alcohol. Afterward, the samples were mixed with FFPE extraction buffer EXB Plus (100 μl per sample; QIAGEN), incubated at 100°C for 20 min, at 80°C for 2 h and then centrifuged for 15 min at 14,000 × *g* at 4°C. The protein concentrations in the supernatant were determined using the Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA).

Western blot analysis
---------------------

Total protein (20 μg) from each sample was mixed with Laemmli sample buffer and heated at 100°C for 5 min. It was then loaded into individual wells, resolved by 8% SDS-PAGE and electroblotted onto nitrocellulose membranes (GE Healthcare Life Sciences, Pittsburgh, PA, USA). Membranes were blocked in 5% nonfat dry milk in Tris-buffered saline with Tween 20 (TBS-T), then incubated with antibodies to Glut-1, CAIX, ATP synthase, glutaminase, MCT-4, LC3A and p62 overnight at 4°C. The membranes were washed with TBS-T and then probed with peroxidase-conjugated goat anti-rabbit immunoglobulin G (1:2,000; Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at room temperature. Washing was repeated and the membranes were developed with an enhanced chemiluminescence agent (Amersham/GE Healthcare Life Sciences, Little Chalfont, UK). Band densities were measured using TINA image software (raytest, Straubenhardt, Germany).

Statistical analyses
--------------------

Data were processed using SPSS for Windows version 12.0 software (SPSS Inc, Chicago, IL, USA). Student's *t*-test and Fisher's exact test were used to examine any differences in continuous and categorical variables, respectively. Significance was assumed when *P* \< 0.05. Kaplan-Meier survival curves and logrank statistics were employed to evaluate time to tumor recurrence and time to survival. Multivariate regression analysis was performed using the Cox proportional hazards model.

Results
=======

Patients' characteristics according to tumor phenotype
------------------------------------------------------

The clinicopathologic characteristics of 740 patients, comprising 298 (40.3%) cases of luminal A, 166 (22.4%) cases of luminal B, 69 (9.3%) cases of HER2 type and 207 (28%) cases of TNBC type, are summarized in Table  [3](#T3){ref-type="table"}. TNBC type had the highest histologic grade, tumor stage and Ki-67 LI (*P* \< 0.001, *P* = 0.002 and *P* \< 0.001, respectively). In addition, HER2 and TNBC types had higher incidences of tumor recurrence and patient death than other types (*P* \< 0.001).

###### 

**Clinicopathologic characteristics of patients according to breast cancer phenotype**^**a**^

  **Parameters**                                         **Total**    **Luminal A**   **Luminal B**    **HER2**      **TNBC**     ***P*-value**
  ---------------------------------------------------- ------------- --------------- --------------- ------------- ------------- ---------------
  Age (years, mean ± SD)                                49.7 ± 11.0    50.6 ± 10.5     48.5 ± 10.1    52.8 ± 9.8    48.4 ± 12.4       0.007
  Histologic grade                                                                                                                   \<0.001
   I                                                    118 (15.9)      90 (30.2)       18 (10.8)       1 (1.4)       9 (4.3)            
   II                                                   373 (50.4)     180 (60.4)       90 (54.2)      35 (50.7)     68 (32.9)           
   III                                                  249 (33.6)      28 (9.4)        58 (34.9)      33 (47.8)    130 (62.8)           
  Tumor stage                                                                                                                         0.002
   T1                                                   358 (48.4)     166 (55.7)       86 (51.8)      31 (44.9)     75 (36.2)           
   T2                                                   367 (49.6)     125 (41.9)       78 (47.0)      37 (53.6)    127 (61.4)           
   T3                                                    15 (2.0)        7 (2.3)         2 (1.2)        1 (1.4)       5 (2.4)            
  Nodal stage                                                                                                                         0.041
   N0                                                   436 (58.9)     168 (56.4)       91 (54.8)      42 (60.9)    135 (65.2)           
   N1                                                   200 (27.0)      90 (30.2)       43 (25.9)      13 (18.8)     54 (26.1)           
   N2                                                    66 (8.9)       27 (9.1)        17 (18.5)      10 (14.5)     12 (5.8)            
   N3                                                    38 (5.1)       13 (4.4)        15 (9.0)        4 (5.8)       6 (2.9)            
  Estrogen receptor status                                                                                                           \<0.001
   Negative                                             286 (38.6)       5 (1.7)         5 (3.0)      69 (100.0)    207 (100.0)          
   Positive                                             454 (61.4)     293 (98.3)      161 (97.0)       0 (0.0)       0 (0.0)            
  Progesterone receptor status                                                                                                       \<0.001
   Negative                                             371 (50.1)      50 (16.8)       46 (27.7)     69 (100.0)    207 (100.0)          
   Positive                                             369 (49.9)     248 (83.2)      120 (72.3)       0 (0.0)       0 (0.0)            
  HER2 status                                                                                                                        \<0.001
   0                                                    290 (39.2)     108 (36.2)       23 (13.9)       0 (0.0)     159 (76.8)           
   1+                                                   186 (25.1)     118 (39.6)       33 (20.0)       0 (0.0)      35 (16.9)           
   2+                                                   142 (19.2)      72 (24.2)       41 (24.7)      16 (23.2)     13 (6.3)            
   3+                                                   122 (16.5)       0 (0.0)        69 (41.6)      53 (76.8)      0 (0.0)            
  Ki-67 LI (%, mean ± SD)                               18.1 ± 19.2     4.7 ± 3.7      19.7 ± 12.7    19.5 ± 12.5   35.6 ± 23.7      \<0.001
  Tumor recurrence                                       69 (9.3)       15 (5.0)        12 (7.2)       11 (15.9)     31 (15.0)       \<0.001
  Patient's death                                        67 (9.1)       14 (4.7)        11 (6.6)       12 (17.4)     30 (14.5)       \<0.001
  Duration of clinical follow-up (months, mean ± SD)    70.2 ± 31.7    72.7 ± 30.0     70.3 ± 30.3    67.1 ± 35.8   67.8 ± 33.8       0.291

^a^LI, labeling index; TNBC triple-negative breast cancer.

Expression of metabolism-related proteins according to tumor phenotype
----------------------------------------------------------------------

The differential expression of metabolism-related proteins according to breast cancer phenotype is summarized in Table  [4](#T4){ref-type="table"}. Tumor expression of Glut-1, MCT4 and LC3A was highest in TNBC and lowest in the luminal A type (*P* \< 0.001). Stromal expression of CAIX and MCT4 and tumor expression of cytoplasmic p62 was highest in HER2 type and lowest in luminal A type (*P* = 0.032, *P* \< 0.001 and *P* \< 0.001, respectively). Tumor expression of CAIX and LC3B was highest in TNBC and lowest in luminal B type (*P* = 0.008 and *P* = 0.013, respectively). HER2 type showed the highest tumor and stromal ATP synthase expression (*P* = 0.027 and *P* \< 0.001, respectively) and stromal glutaminase expression (*P* = 0.001), whereas luminal A type showed the lowest expression of those markers. Expression of stromal LC3A and tumor expression of nuclear p62 were highest in luminal A and lowest in TNBC (*P* \< 0.001).

###### 

**Expression of metabolism-related proteins according to breast cancer phenotype**^**a**^

  **Parameters**             **Total**    **Luminal A**   **Luminal B**   **HER2**    **TNBC**      ***P*-value**
  -------------------------- ------------ --------------- --------------- ----------- ------------- ---------------
  Glut-1 in tumor                                                                                   \<0.001
   Negative                  504 (68.1)   260 (87.2)      124 (74.7)      47 (68.1)   73 (35.3)      
   Positive                  236 (31.9)   38 (12.8)       42 (25.3)       22 (31.9)   134 (64.7)     
  Glut-1 in stroma                                                                                  0.103
   Negative                  724 (97.8)   296 (99.3)      162 (97.6)      66 (95.7)   200 (96.6)     
   Positive                  16 (2.2)     2 (0.7)         4 (2.4)         3 (4.3)     7 (3.4)        
  CAIX in tumor                                                                                     0.008
   Negative                  520 (70.3)   217 (72.8)      127 (76.5)      49 (71.0)   127 (61.3)     
   Positive                  220 (29.7)   81 (27.2)       39 (23.5)       20 (29.0)   80 (38.6)      
  CAIX in stroma                                                                                    0.032
   Negative                  627 (84.7)   264 (88.6)      137 (82.5)      52 (75.4)   174 (84.1)     
   Positive                  113 (15.3)   34 (11.4)       29 (17.5)       17 (24.6)   33 (15.9)      
  ATP synthase in tumor                                                                             0.027
   Negative                  30 (4.1)     20 (6.7)        4 (2.4)         1 (1.4)     5 (2.4)        
   Positive                  710 (95.9)   278 (93.3)      162 (97.6)      68 (98.6)   202 (97.6)     
  ATP synthase in stroma                                                                            \<0.001
   Negative                  570 (77.0)   256 (85.9)      112 (67.5)      38 (55.1)   164 (79.2)     
   Positive                  170 (23.0)   42 (14.1)       54 (32.5)       31 (44.9)   43 (20.8)      
  Glutaminase in tumor                                                                              0.164
   Negative                  219 (29.6)   85 (28.5)       60 (36.1)       21 (30.4)   53 (25.6)      
   Positive                  521 (70.4)   213 (71.5)      106 (63.9)      48 (69.6)   154 (74.4)     
  Glutaminase in stroma                                                                             0.001
   Negative                  495 (66.9)   223 (74.8)      105 (63.3)      39 (56.5)   128 (61.8)     
   Positive                  245 (33.1)   75 (25.2)       61 (36.7)       30 (43.5)   79 (38.2)      
  BNIP3 in tumor                                                                                    0.262
   Negative                  504 (68.1)   206 (69.1)      112 (67.5)      40 (58.0)   146 (70.5)     
   Positive                  236 (31.9)   92 (30.9)       54 (32.5)       29 (42.0)   61 (29.5)      
  BNIP3 in stroma                                                                                   0.262
   Negative                  700 (94.6)   281 (94.3)      159 (95.8)      62 (89.9)   198 (95.7)     
   Positive                  40 (5.4)     17 (5.7)        7 (4.2)         7 (10.1)    9 (4.3)        
  MCT4 in tumor                                                                                     \<0.001
   Negative                  540 (73.0)   253 (84.9)      118 (71.1)      49 (71.0)   120 (58.0)     
   Positive                  200 (27.0)   45 (15.1)       48 (28.9)       20 (29.0)   87 (42.0)      
  MCT4 in stroma                                                                                    \<0.001
   Negative                  418 (56.5)   222 (74.5)      81 (48.8)       23 (33.3)   92 (44.4)      
   Positive                  322 (43.5)   76 (25.5)       85 (51.2)       46 (66.7)   115 (55.6)     
  Cytoplasmic Beclin-1                                                                              0.137
   Negative                  406 (54.9)   169 (56.7)      99 (59.6)       31 (44.9)   107 (51.7)     
   Positive                  334 (45.1)   129 (43.3)      67 (33.7)       38 (55.1)   100 (48.3)     
  Nuclear Beclin-1                                                                                  \<0.001
   Negative                  666 (90.0)   262 (87.9)      152 (91.6)      55 (79.7)   197 (95.2)     
   Positive                  74 (10.0)    36 (12.1)       14 (8.4)        14 (20.3)   10 (4.8)       
  LC3A in tumor                                                                                     \<0.001
   Negative                  669 (90.4)   294 (98.7)      158 (95.2)      68 (98.6)   149 (72.0)     
   Positive                  71 (9.6)     4 (1.3)         8 (4.8)         1 (1.4)     58 (28.0)      
  LC3A in stroma                                                                                    \<0.001
   Negative                  687 (92.8)   267 (89.6)      151 (91.0)      62 (89.9)   207 (100.0)    
   Positive                  53 (7.2)     31 (10.4)       15 (9.0)        7 (10.1)    0 (0.0)        
  LC3B in tumor                                                                                     0.013
   Negative                  475 (64.2)   186 (62.4)      124 (74.7)      42 (60.9)   123 (59.4)     
   Positive                  265 (35.8)   112 (37.6)      42 (25.3)       27 (39.1)   84 (40.6)      
  LC3B in stroma                                                                                    0.645
   Negative                  688 (93.0)   277 (93.0)      151 (91.0)      65 (94.2)   195 (94.2)     
   Positive                  52 (7.0)     21 (7.0)        15 (9.0)        4 (5.8)     12 (5.8)       
  Cytoplasmic p62 in tumor                                                                          \<0.001
   Negative                  274 (37.0)   131 (44.0)      51 (30.7)       15 (21.7)   77 (37.2)      
   Positive                  466 (63.0)   167 (56.0)      115 (69.3)      54 (78.3)   130 (62.8)     
  Nuclear p62 in tumor                                                                              \<0.001
   Negative                  532 (71.9)   180 (60.4)      131 (78.9)      44 (63.8)   177 (85.5)     
   Positive                  208 (28.1)   118 (39.6)      35 (21.1)       25 (36.2)   30 (14.5)      
  Nuclear p62 in stroma                                                                             0.876
   Negative                  512 (69.2)   206 (69.1)      115 (69.3)      45 (65.2)   146 (70.5)     
   Positive                  228 (30.8)   92 (30.9)       51 (30.7)       24 (34.8)   61 (29.5)      

^a^BNIP3, BCL2/adenovirus E1B 19-kDa interacting protein 3; CAIX, carbonic anhydrase IX; Glut-1, glucose transporter 1; LC3A, microtubule-associated protein 1 light chain 3α; LC3B, microtubule-associated protein 1 light chain 3β; MCT4, monocarboxylate transporter 4; TNBC, triple-negative breast cancer.

Correlation between metabolism-related proteins and clinicopathologic factors
-----------------------------------------------------------------------------

The correlation between expression of metabolism-related proteins and clinicopathologic parameters is summarized in Table  [5](#T5){ref-type="table"}. Tumor expression of Glut-1 was associated with higher histologic grade (*P \<* 0.001), ER negativity (*P \<* 0.001), higher T stage (*P \<* 0.001) and higher Ki-67 LI (*P \<* 0.001), whereas CAIX was associated with higher Ki-67 LI (*P \<* 0.001). Stromal ATP synthase expression was associated with HER2 positivity (*P* \< 0.001), and stromal glutaminase expression was associated with higher KI-67 LI (*P* = 0.021). Tumor expression of MCT4 was associated with higher histologic grade (*P \<* 0.001), ER negativity (*P \<* 0.001), PR negativity (*P \<* 0.001), higher T stage (*P \<* 0.001) and higher Ki-67 LI (*P \<* 0.001). Stromal expression of MCT4 was associated with higher histologic grade (*P \<* 0.001), ER negativity (*P \<* 0.001), PR negativity (*P \<* 0.001), HER2 positivity (*P \<* 0.001) and higher Ki-67 LI (*P \<* 0.001). Tumor expression of LC3A was associated with higher histologic grade (*P \<* 0.001), ER negativity (*P \<* 0.001), PR negativity (*P \<* 0.001), HER2 negativity (*P \<* 0.001) and higher Ki-67 LI (*P \<* 0.001). In contrast, stromal expression of LC3A was associated with ER positivity (*P \<* 0.001), PR positivity (*P* \< 0.001) and lower Ki-67 LI (*P* = 0.032). Tumor expression of cytoplasmic p62 was associated with HER2 positivity (*P* \< 0.001), whereas nuclear p62 was associated with lower histologic grade (*P* \< 0.001), ER positivity (*P* \< 0.001), PR positivity (*P* \< 0.001) and lower Ki-67 LI (*P* \< 0.001).

###### 

**Correlations between the expression of metabolism-related proteins and clinicopathologic parameters**^**a**^

  **Parameters**            **Glut-1 in tumor**         **Glut-1 in stroma**         **CAIX in tumor**              **CAIX in stroma**                                                                                                                                                                                                                    
  ------------------------- --------------------------- ---------------------------- ------------------------------ --------------------------- --------------------------- --------------- -------------------- -------------------- --------------- -------------------- -------------------- --------------- -------------------- -------------------- ---------------
  Age (years, mean ± SD)    50.5 ± 10.7                 48.1 ± 11.4                  0.126                          49.7 ± 110.0                49.3 ± 9.0                  18.14           49.7 ± 11.0          49.8 ± 11.0          19.67           49.3 ± 11.1          51.7 ± 10.3          0.840                                                      
  Histologic grade                                                                   \<0.001                                                                                8.946                                                     0.441                                                     0.483                                                      
   I/II                     392 (71.8)                  99 (41.9)                                                   482 (67.3)                  9 (56.3)                                    359 (69.0)           132 (60.0)                           427 (68.1)           64 (56.6)                                                                       
   III                      112 (22.2)                  137 (58.1)                                                  242 (33.4)                  7 (43.7)                                    161 (31.0)           88 (40.0)                            200 (31.9)           49 (43.4)                                                                       
  ER                                                                                 \<0.001                                                                                0.378                                                     0.042                                                     1.113                                                      
   Negative                 128 (25.4)                  158 (66.9)                                                  275 (38.0)                  11 (68.8)                                   182 (35.0)           104 (47.3)                           233 (37.2)           53 (46.9)                                                                       
   Positive                 376 (74.6)                  78 (33.1)                                                   449 (62.0)                  5 (31.2)                                    338 (65.0)           116 (52.7)                           394 (62.8)           60 (53.1)                                                                       
  PR                                                                                 \<0.001                                                                                4.305                                                     10.92                                                     8.715                                                      
   Negative                 190 (37.7)                  182 (77.1)                                                  361 (49.9)                  11 (68.8)                                   257 (49.4)           115 (52.3)                           311 (49.6)           61 (54.0)                                                                       
   Positive                 314 (62.3)                  54 (22.9)                                                   363 (50.1)                  5 (31.2)                                    263 (50.6)           105 (47.7)                           316 (50.4)           52 (46.0)                                                                       
  HER2                                                                               0.714                                                                                  6.741                                                     0.294                                                     1.260                                                      
   Negative                 386 (76.6)                  197 (83.5)                                                  572 (79.0)                  11 (68.8)                                   397 (76.3)           186 (84.5)                           502 (80.1)           81 (71.7)                                                                       
   Positive                 118 (23.4)                  39 (16.5)                                                   152 (21.0)                  5 (31.2)                                    123 (23.7)           34 (15.5)                            125 (19.9)           32 (28.3)                                                                       
  Tumor stage                                                                        \<0.001                                                                                18.81                                                     19.65                                                     3.192                                                      
   T1                       270 (53.6)                  88 (37.3)                                                   350 (48.3)                  8 (50.0)                                    251 (48.3)           107 (48.6)                           296 (47.2)           62 (54.9)                                                                       
   T2/T3                    234 (46.4)                  148 (62.7)                                                  374 (51.7)                  8 (50.0)                                    269 (51.7)           113 (51.4)                           331 (52.8)           51 (45.1)                                                                       
  Nodal stage                                                                        1.932                                                                                  16.12                                                     15.62                                                     15.87                                                      
   N0                       286 (56.7)                  150 (63.6)                                                  426 (58.8)                  10 (62.5)                                   304 (58.5)           132 (60.0)                           371 (59.2)           65 (57.5)                                                                       
   N1/N2/N3                 218 (43.3)                  86 (36.4)                                                   298 (41.2)                  6 (37.5)                                    216 (41.5)           88 (40.0)                            256 (40.8)           48 (42.5)                                                                       
  Ki-67 LI (%, mean ± SD)   12.7 ± 14.9                 29.6 ± 22.1                  \<0.001                        18.0 ± 19.3                 22.5 ± 14.7                 7.497           16.1 ± 17.5          22.7 ± 22.1          \<0.001         17.8 ± 19.7          19.5 ± 16.7          8.505                                                      
  Tumor recurrence                                                                   0.210                                                                                  8.106                                                     18.62                                                     17.85                                                      
   Absent                   467 (92.7)                  204 (86.4)                                                  655 (90.5)                  16 (100.0)                                  471 (90.6)           200 (90.9)                           568 (90.6)           103 (91.2)                                                                      
   Present                  37 (7.3)                    32 (13.6)                                                   69 (9.5)                    0 (0.0)                                     49 (9.4)             20 (9.1)                             59 (9.4)             10 (9.8)                                                                        
  Death                                                                              0.420                                                                                  8.085                                                     11.76                                                     15.22                                                      
   Survival                 467 (92.7)                  206 (87.3)                                                  657 (90.7)                  16 (100.0)                                  475 (91.3)           198 (90.0)                           571 (91.1)           102 (90.3)                                                                      
   Death                    37 (7.3)                    30 (12.7)                                                   67 (9.3)                    0 (0.0)                                     45 (8.7)             22 (10.0)                            56 (8.9)             11 (9.7)                                                                        
  **Parameters**            **ATP synthase in tumor**   **ATP synthase in stroma**   **Glutaminase in tumor**       **Glutaminase in stroma**                                                                                                                                                                                                             
                            **Negative**                **Positive**                                                **Negative**                **Positive**                                **Negative**         **Positive**                         **Negative**         **Positive**                                                                    
                            **(*n*= 30) (%)**           **(*n*= 710) (%)**           ***P*-value**                  **(*n*= 570) (%)**          **(*n*= 170) (%)**          ***P*-value**   **(*n*= 219) (%)**   **(*n*= 521) (%)**   ***P*-value**   **(*n*= 495) (%)**   **(*n*= 245) (%)**   ***P*-value**                                              
  Age (years, mean ± SD)    46.7 ± 9.3                  49.9 ± 11.0                  2.478                          49.5 ± 11.2                 50.4 ± 10.0                 7.539           49.2 ± 11.6          49.9 ± 10.7          11.90           49.5 ± 11.1          50.4 ± 10.7          5.124                                                      
  Histologic grade                                                                   11.63                                                                                  0.252                                                     16.77                                                     0.168                                                      
   I/II                     22 (733)                    469 (66.1)                                                  392 (68.8)                  99 (58.2)                                   147 (67.1)           344 (66.0)                           345 (69.7)           146 (59.6)                                                                      
   III                      8 (26.7)                    241 (33.9)                                                  178 (31.2)                  71 (41.8)                                   72 (32.9)            177 (34.0)                           150 (30.3)           99 (40.4)                                                                       
  ER                                                                                 1.827                                                                                  1.533                                                     4.536                                                     0.126                                                      
   Negative                 7 (23.3)                    279 (39.3)                                                  210 (36.8)                  76 (44.7)                                   77 (35.2)            209 (40.1)                           174 (35.2)           112 (45.7)                                                                      
   Positive                 23 (76.7)                   431 (60.7)                                                  360 (63.2)                  94 (55.3)                                   142 (64.8)           312 (59.9)                           321 (64.8)           133 (54.3)                                                                      
  PR                                                                                 0.189                                                                                  0.609                                                     4.158                                                     0.735                                                      
   Negative                 8 (26.7)                    364 (51.3)                                                  274 (48.1)                  98 (57.6)                                   102 (46.6)           270 (51.8)                           235 (47.5)           137 (55.9)                                                                      
   Positive                 22 (73.3)                   346 (48.7)                                                  296 (51.9)                  72 (42.4)                                   117 (53.4)           251 (48.2)                           260 (52.5)           108 (44.1)                                                                      
  HER2                                                                               3.570                                                                                  \<0.001                                                   13.08                                                     3.822                                                      
   Negative                 27 (90.0)                   556 (78.3)                                                  472 (82.8)                  111 (65.3)                                  170 (77.6)           413 (79.3)                           397 (80.2)           186 (75.9)                                                                      
   Positive                 3 (10.0)                    154 (21.7)                                                  98 (17.2)                   59 (34.7)                                   49 (22.4)            108 (20.7)                           98 (19.8)            59 (24.1)                                                                       
  Tumor stage                                                                        7.539                                                                                  21.00                                                     7.875                                                     18.39                                                      
   T1                       12 (40.0)                   346 (48.7)                                                  276 (48.4)                  82 (48.2)                                   100 (45.7)           258 (49.5)                           238 (48.1)           120 (49.0)                                                                      
   T2/T3                    18 (60.0)                   364 (51.3)                                                  294 (51.6)                  88 (51.8)                                   119 (54.3)           263 (50.5)                           257 (51.9)           125 (51.0)                                                                      
  Nodal stage                                                                        7.266                                                                                  6.027                                                     7.728                                                     8.967                                                      
   N0                       15 (50.0)                   421 (59.3)                                                  342 (60.0)                  94 (55.3)                                   135 (61.6)           301 (57.8)                           297 (60.0)           139 (56.7)                                                                      
   N1/N2/N3                 15 (50.0)                   289 (40.7)                                                  228 (40.0)                  76 (44.7)                                   84 (38.4)            220 (42.2)                           198 (40.0)           106 (43.3)                                                                      
  Ki-67 LI (%, mean ± SD)   9.8 ± 11.7                  18.4 ± 19.4                  0.336                          17.3 ± 19.7                 20.8 ± 17.5                 0.798           18.6 ± 20.0          17.8 ± 18.9          13.50           15.6 ± 17.2          22.9 ± 22.0          0.021                                                      
  Tumor recurrence                                                                   10.79                                                                                  21.00                                                     7.014                                                     10.56                                                      
   Absent                   26 (86.7)                   645 (90.8)                                                  517 (90.7)                  154 (90.6)                                  195 (89.0)           476 (91.4)                           446 (90.1)           225 (91.8)                                                                      
   Present                  4 (13.3)                    65 (9.2)                                                    53 (9.3)                    16 (9.4)                                    24 (11.0)            45 (8.6)                             49 (9.9)             20 (8.2)                                                                        
  Death                                                                              15.68                                                                                  13.60                                                     3.381                                                     8.757                                                      
   Survival                 27 (90.0)                   646 (91.0)                                                  520 (91.2)                  153 (90.0)                                  194 (88.6)           479 (91.9)                           447 (90.3)           226 (92.2)                                                                      
   Death                    3 (10.0)                    64 (9.0)                                                    50 (8.8)                    17 (10.0)                                   25 (11.4)            42 (8.1)                             48 (9.7)             19 (7.8)                                                                        
  **Parameters**            **BNIP3 in tumor**          **BNIP3 in stroma**          **MCT4 in tumor**              **MCT4 in stroma**                                                                                                                                                                                                                    
  **Negative**              **Positive**                                             **Negative**                   **Positive**                                            **Negative**    **Positive**                              **Negative**    **Positive**                                                                                        
                            **(*n*=504) (%)**           **(*n*= 236) (%)**           ***P*-value**                  **(*n*= 700) (%)**          **(*n*= 40) (%)**           ***P*-value**   **(*n*= 540) (%)**   **(*n*= 200) (%)**   ***P*-value**   **(*n*= 418) (%)**   **(*n*= 322) (%)**   ***P*-value**                                              
  Age (years, mean ± SD)    48.9 ± 10.9                 51.6 ± 11.0                  0.042                          49.5 ± 10.8                 53.2 ± 12.7                 0.882           49.8 ± 11.1          49.6 ± 10.6          17.91           49.6 ± 11.0          49.5 ± 10.9          14.80                                                      
  Histologic grade                                                                   5.859                                                                                  15.37                                                     \<0.001                                                   \<0.001                                                    
   I/II                     341 (67.7)                  150 (63.6)                                                  463 (66.1)                  28 (70.0)                                   386 (71.5)           105 (52.5)                           314 (75.1)           177 (55.0)                                                                      
   III                      163 (32.3)                  86 (36.4)                                                   237 (33.9)                  12 (30.0)                                   154 (28.5)           95 (47.5)                            104 (24.9)           145 (45.0)                                                                      
  ER                                                                                 14.40                                                                                  12.99                                                     \<0.001                                                   \<0.001                                                    
   Negative                 192 (38.1)                  94 (39.8)                                                   269 (38.4)                  17 (42.5)                                   174 (32.2)           112 (56.0)                           123 (29.4)           163 (50.6)                                                                      
   Positive                 312 (61.9)                  142 (60.2)                                                  431 (61.6)                  23 (57.5)                                   366 (67.8)           88 (44.0)                            295 (70.6)           159 (49.4)                                                                      
  PR                                                                                 17.07                                                                                  8.757                                                     \<0.001                                                   \<0.001                                                    
   Negative                 255 (50.6)                  117 (49.6)                                                  349 (49.9)                  23 (57.5)                                   232 (43.0)           140 (70.0)                           179 (42.8)           193 (60.0)                                                                      
   Positive                 249 (49.4)                  119 (50.4)                                                  351 (50.1)                  17 (42.5)                                   308 (57.0)           60 (30.0)                            239 (57.2)           129 (40.0)                                                                      
  HER2                                                                               4.410                                                                                  6.762                                                     11.42                                                     \<0.001                                                    
   Negative                 404 (80.2)                  179 (75.8)                                                  554 (79.1)                  29 (72.5)                                   422 (78.1)           161 (80.5)                           356 (85.2)           227 (70.5)                                                                      
   Positive                 100 (19.8)                  57 (24.2)                                                   146 (20.9)                  11 (27.5)                                   118 (21.9)           39 (19.5)                            62 (14.8)            95 (29.5)                                                                       
  Tumor stage                                                                        1.449                                                                                  15.66                                                     \<0.001                                                   7.854                                                      
   T1                       232 (46.0)                  126 (53.4)                                                  340 (48.6)                  18 (45.0)                                   283 (52.4)           75 (37.5)                            196 (46.9)           162 (50.3)                                                                      
   T2/T3                    272 (54.0)                  110 (46.6)                                                  360 (51.4)                  22 (55.0)                                   257 (47.6)           125 (62.5)                           222 (53.1)           160 (49.7)                                                                      
  Nodal stage                                                                        6.237                                                                                  0.630                                                     18.20                                                     7.686                                                      
   N0                       290 (57.5)                  146 (61.9)                                                  419 (59.9)                  17 (42.5)                                   317 (58.7)           119 (59.5)                           240 (57.4)           196 (60.9)                                                                      
   N1/N2/N3                 214 (42.5)                  90 (38.1)                                                   281 (40.1)                  23 (57.5)                                   223 (41.3)           81 (40.5)                            178 (42.6)           126 (39.1)                                                                      
  Ki-67 LI (%, mean ± SD)   18.9 ± 20.9                 16.2 ± 15.0                  1.680                          18.3 ± 19.5                 14.6 ± 13.7                 5.208           15.3 ± 17.8          25.6 ± 21.0          \<0.001         13.2 ± 16.5          24.3 ± 20.7          \<0.001                                                    
  Tumor recurrence                                                                   0.021                                                                                  3.444                                                     14.11                                                     11.00                                                      
   Absent                   445 (88.3)                  226 (95.8)                                                  632 (90.3)                  39 (97.5)                                   491 (90.9)           180 (90.0)                           376 (90.0)           295 (91.6)                                                                      
   Present                  59 (11.7)                   10 (4.2)                                                    68 (9.7)                    1 (2.5)                                     49 (9.1)             20 (10.0)                            42 (10.0)            27 (8.4)                                                                        
  Death                                                                              5.712                                                                                  15.22                                                     11.90                                                     2.562                                                      
   Survival                 454 (90.1)                  219 (92.8)                                                  636 (90.9)                  37 (92.5)                                   493 (91.3)           180 (90.0)                           374 (89.5)           299 (92.9)                                                                      
   Death                    50 (9.9)                    17 (7.2)                                                    64 (9.1)                    3 (7.5)                                     47 (8.7)             20 (10.0)                            44 (10.5)            23 (7.1)                                                                        
  **Parameters**            **Cytoplasmic Beclin-1**    **Nuclear Beclin-1**         **LC3A in tumor**              **LC3A in stroma**                                                                                                                                                                                                                    
  **Negative**              **Positive**                                             **Negative**                   **Positive**                                            **Negative**    **Positive**                              **Negative**    **Positive**                                                                                        
                            **(*n*= 406) (%)**          **(*n*= 334) (%)**           ***P*-value**                  **(*n*= 666) (%)**          **(*n*= 74) (%)**           ***P*-value**   **(*n*= 669) (%)**   **(*n*= 71) (%)**    ***P*-value**   **(*n*= 687) (%)**   **(*n*= 53) (%)**    ***P*-value**                                              
  Age (years, mean ± SD)    48.6 ± 10.5                 51.1 ± 11.4                  0.042                          49.6 ± 11.1                 50.8 ± 9.9                  8.316           50.2 ± 11.0          45.6 ± 9.8           0.021           49.7 ± 11.0          49.6 ± 9.2           19.65                                                      
  Histologic grade                                                                   14.61                                                                                  \<0.001                                                   \<0.001                                                   1.029                                                      
   I/II                     272 (67.0)                  219 (65.6)                                                  427 (64.1)                  64 (86.5)                                   470 (70.3)           21 (29.6)                            449 (65.4)           42 (79.2)                                                                       
   III                      134 (33.0)                  115 (34.4)                                                  239 (35.9)                  10 (13.5)                                   199 (29.7)           50 (70.4)                            238 (34.6)           11 (20.8)                                                                       
  ER                                                                                 6.090                                                                                  8.022                                                     \<0.001                                                   \<0.001                                                    
   Negative                 143 (35.2)                  143 (42.8)                                                  261 (39.2)                  25 (33.8)                                   226 (33.8)           60 (84.5)                            278 (40.5)           8 (15.1)                                                                        
   Positive                 263 (64.8)                  191 (57.2)                                                  405 (60.8)                  49 (66.2)                                   443 (66.2)           11 (15.5)                            409 (59.5)           45 (84.9)                                                                       
  PR                                                                                 19.76                                                                                  1.827                                                     \<0.001                                                   \<0.001                                                    
   Negative                 205 (50.5)                  167 (50.0)                                                  342 (51.4)                  30 (40.5)                                   309 (46.2)           63 (88.7)                            360 (52.4)           12 (22.6)                                                                       
   Positive                 201 (49.5)                  167 (50.0)                                                  324 (48.6)                  44 (59.5)                                   360 (53.8)           8 (11.3)                             327 (47.6)           41 (77.4)                                                                       
  HER2                                                                               12.36                                                                                  0.336                                                     \<0.001                                                   8.022                                                      
   Negative                 323 (79.6)                  260 (77.8)                                                  533 (80.0)                  50 (67.6)                                   515 (76.9)           68 (95.8)                            544 (79.2)           39 (73.6)                                                                       
   Positive                 83 (20.4)                   74 (22.2)                                                   133 (20.0)                  24 (32.4)                                   154 (23.1)           3 (4.2)                              143 (20.8)           14 (26.4)                                                                       
  Tumor stage                                                                        0.042                                                                                  6.888                                                     16.86                                                     0.210                                                      
   T1                       175 (43.1)                  183 (54.8)                                                  318 (47.7)                  40 (54.1)                                   325 (48.6)           33 (46.5)                            323 (47.0)           35 (66.0)                                                                       
   T2/T3                    231 (56.9)                  151 (45.2)                                                  348 (52.3)                  34 (45.9)                                   344 (51.4)           38 (53.5)                            364 (53.0)           18 (34.0)                                                                       
  Nodal stage                                                                        13.71                                                                                  3.612                                                     6.552                                                     16.23                                                      
   N0                       236 (58.1)                  200 (59.9)                                                  398 (59.8)                  38 (51.4)                                   390 (58.3)           46 (64.8)                            406 (59.1)           30 (56.6)                                                                       
   N1/N2/N3                 170 (41.9)                  134 (40.1)                                                  268 (40.2)                  36 (48.6)                                   279 (41.7)           25 (35.2)                            281 (40.9)           23 (43.4)                                                                       
  Ki-67 LI (%, mean ± SD)   17.8 ± 19.4                 18.3 ± 19.1                  0.042                          19.0 ± 19.8                 9.5 ± 10.0                  \<0.001         15.7 ± 17.2          39.6 ± 23.1          \<0.001         18.7 ± 19.7          10.4 ± 9.6           0.032                                                      
  Tumor recurrence                                                                   0.882                                                                                  2.877                                                     4.053                                                     16.98                                                      
   Absent                   360 (88.7)                  311 (93.1)                                                  600 (90.1)                  71 (95.9)                                   610 (91.2)           61 (85.9)                            622 (90.5)           49 (92.5)                                                                       
   Present                  46 (11.3)                   23 (6.9)                                                    66 (9.9)                    3 (4.1)                                     59 (8.8)             10 (14.1)                            65 (9.5)             4 (7.5)                                                                         
  Death                                                                              16.75                                                                                  0.189                                                     10.75                                                     9.765                                                      
   Survival                 368 (90.6)                  305 (91.3)                                                  600 (90.1)                  73 (98.6)                                   610 (91.2)           63 (88.7)                            623 (90.7)           50 (94.3)                                                                       
   Death                    38 (9.4)                    29 (8.7)                                                    66 (9.9)                    1 (1.4)                                     59 (8.8)             8 (11.3)                             64 (9.3)             3 (5.7)                                                                         
  **Parameters**            **LC3B in tumor**           **LC3B in stroma**           **Cytoplasmic p62 in tumor**   **Nuclear p62 in tumor**    **Nuclear p62 in stroma**                                                                                                                                                                                 
  **Negative**              **Positive**                                             **Negative**                   **Positive**                                            **Negative**    **Positive**                              **Negative**    **Positive**                              **Negative**    **Positive**                              
                            **(*n*= 475) (%)**          **(n = 265) (%)**            ***P*-value**                  **(*n*= 688) (%)**          **(*n*= 52) (%)**           ***P*-value**   **(*n*= 274) (%)**   **(*n*= 466) (%)**   ***P*-value**   **(*n*= 532) (%)**   **(*n*= 208) (%)**   ***P*-value**   **(*n*= 512) (%)**   **(*n*= 228) (%)**   ***P*-value**
  Age                       49.4 ± 10.4                 50.4 ± 12.0                  4.599                          49.6 ± 11.0                 51.1 ± 10.6                 15.77           49.4 ± 10.3          49.9 ± 11.4          10.35           49.4 ± 10.9          50.6 ± 11.2          3.717           49.5 ± 11.2          50.3 ± 10.4          6.741
  (years, mean ± SD)                                                                                                                                                                                                                                                                                                                                      
  Histologic grade                                                                   3.528                                                                                  9.450                                                     0.210                                                     \<0.001                                                   18.18
   I/II                     324 (68.2)                  167 (63.0)                                                  459 (66.7)                  32 (61.5)                                   198 (72.3)           293 (62.9)                           322 (60.5)           169 (81.3)                           341 (66.6)           150 (65.8)            
   III                      151 (31.8)                  98 (37.0)                                                   229 (33.3)                  20 (38.5)                                   76 (27.7)            173 (37.1)                           210 (39.5)           39 (18.8)                            171 (33.4)           78 (34.2)             
  ER                                                                                 6.279                                                                                  7.980                                                     2.877                                                     \<0.001                                                   14.34
   Negative                 173 (36.4)                  113 (42.6)                                                  269 (39.1)                  17 (32.7)                                   96 (35.0)            190 (40.8)                           227 (42.7)           59 (28.4)                            195 (38.1)           91 (39.9)             
   Positive                 302 (63.6)                  152 (57.4)                                                  419 (60.9)                  35 (67.3)                                   178 (65.0)           276 (59.2)                           305 (57.3)           149 (71.6)                           317 (61.9)           137 (60.1)            
  PR                                                                                 10.29                                                                                  5.292                                                     0.105                                                     \<0.001                                                   17.05
   Negative                 234 (49.3)                  138 (52.1)                                                  350 (50.9)                  22 (42.3)                                   119 (43.4)           253 (54.3)                           293 (55.1)           79 (38.0)                            259 (50.6)           113 (49.6)            
   Positive                 241 (50.7)                  127 (47.9)                                                  338 (49.1)                  30 (57.7)                                   155 (56.6)           213 (45.7)                           239 (44.9)           129 (62.0)                           253 (49.4)           115 (50.4)            
  HER2                                                                               12.07                                                                                  12.55                                                     \<0.001                                                   16.04                                                     13.16
   Negative                 371 (78.1)                  212 (80.0)                                                  540 (78.5)                  43 (82.7)                                   238 (86.9)           345 (74.0)                           421 (79.1)           162 (77.9)                           406 (79.3)           177 (34.6)            
   Positive                 104 (21.9)                  53 (20.0)                                                   148 (21.5)                  9 (17.3)                                    36 (13.1)            121 (26.0)                           111 (20.9)           46 (22.1)                            106 (20.7)           51 (22.4)             
  Tumor stage                                                                        0.357                                                                                  14.00                                                     3.570                                                     0.189                                                     0.189
   T1                       214 (45.1)                  144 (54.3)                                                  331 (48.1)                  27 (51.9)                                   142 (51.8)           216 (46.4)                           241 (45.3)           117 (56.2)                           231 (45.1)           127 (55.7)            
   T2/T3                    261 (54.9)                  121 (45.7)                                                  357 (51.9)                  25 (48.1)                                   132 (48.2)           250 (53.6)                           291 (54.7)           91 (43.8)                            281 (54.9)           101 (44.3)            
  Nodal stage                                                                        6.531                                                                                  13.90                                                     3.969                                                     5.901                                                     10.87
   N0                       273 (57.5)                  163 (61.5)                                                  407 (59.2)                  29 (55.8)                                   170 (62.0)           266 (57.1)                           320 (60.2)           116 (55.8)                           306 (59.8)           130 (57.0)            
   N1/N2/N3                 202 (42.5)                  102 (38.5)                                                  281 (40.8)                  23 (44.2)                                   104 (38.0)           200 (42.9)                           212 (39.8)           92 (44.2)                            206 (40.2)           98 (43.0)             
  Ki-67 LI (%, mean ± SD)   18.2 ± 19.8                 17.8 ± 18.2                  16.10                          18.4 ± 19.4                 18.9 ± 17.6                 15.77           16.0 ± 19.2          19.3 ± 19.2          0567            21.4 ± 20.8          9.5 ± 10.6           \<0.001         18.5 ± 19.7          17.0 ± 18.1          7.161
  Tumor recurrence                                                                   18.81                                                                                  9.765                                                     18.83                                                     3.339                                                     19.80
   Absent                   430 (90.5)                  241 (90.9)                                                  622 (90.4)                  49 (94.2)                                   248 (90.5)           423 (90.8)                           477 (89.7)           194 (93.3)                           464 (90.6)           207 (90.8)            
   Present                  45 (9.5)                    24 (9.1)                                                    66 (9.6)                    3 (5.8)                                     26 (9.5)             43 (9.2)                             55 (10.3)            14 (6.7)                             48 (9.4)             21 (9.2)              
  Death                                                                              8.925                                                                                  12.89                                                     14.53                                                     10.03                                                     14.28
   Survival                 435 (91.6)                  238 (89.8)                                                  624 (90.7)                  49 (94.2)                                   251 (91.6)           422 (90.6)                           481 (90.4)           192 (92.3)                           467 (91.2)           206 (90.3)            
   Death                    40 (8.4)                    27 (10.2)                                                   64 (9.3)                    3 (5.8)                                     23 (8.4)             44 (9.4)                             51 (9.6)             16 (7.7)                             45 (8.8)             22 (9.7)              

^a^*P*-values are corrected for multiple testing using the Bonferroni correction. BNIP3, BCL2/adenovirus E1B 19-kDa interacting protein 3; CAIX, carbonic anhydrase IX; Glut-1, glucose transporter 1; LC3A, microtubule-associated protein 1 light chain 3α; LC3B, microtubule-associated protein 1 light chain 3β; LI, labeling index; MCT4, monocarboxylate transporter 4; TNBC, triple-negative breast cancer.

Correlation between tumor metabolic phenotype and clinicopathologic factors
---------------------------------------------------------------------------

The correlation between the metabolic phenotype of breast cancer and clinicopathologic parameters is summarized in Table  [6](#T6){ref-type="table"} and Figure  [1](#F1){ref-type="fig"}. The metabolic phenotype was the Warburg type (*n* = 298, 40.3%), the null type (*n* = 326, 44.0%), the mixed type (*n* = 62, 8.4%) and the reverse Warburg type (*n* = 54, 7.3%). Histologic grade was highest in the mixed type and lowest in the null type (*P* \< 0.001). The mixed type had the highest percentage of ER and PR negativity, and the null type had the highest percentage of ER and PR positivity (*P* \< 0.001). The Warburg type had the highest percentage of negative HER2 status (*P* = 0.006). The Warburg and mixed types comprised the highest percentage of TNBC, and the reverse Warburg and null types comprised the highest percentage of luminal A types (*P* \< 0.001). Stromal expression of ATP synthase and glutaminase was high in the reverse Warburg and mixed types and low in the Warburg and null types (*P* \< 0.001). For the status of tumor autophagy, the mixed type had the highest percentage of activated tumor autophagy and the null type had the highest percentage of nonactivated tumor autophagy (*P* \< 0.001). For the status of stromal autophagy, the reverse Warburg and mixed types had a higher percentage of activation than other types (*P* \< 0.001). Tumor expression of MCT4 was highest in the Warburg type and lowest in the null type (*P* \< 0.001), whereas stromal expression of MCT4 was highest in the mixed type and lowest in the null type (*P* \< 0.001). Ki-67 LI was highest in the mixed type and lowest in the null type (*P* \< 0.001).

###### 

**Clinicopathologic characteristics of patients according to metabolic phenotype**^**a**^

  **Parameters**                 **Warburg type**   **Reverse Warburg**   **Mixed type**   **Null type**   ***P*-value**
  ------------------------------ ------------------ --------------------- ---------------- --------------- ---------------
  Age (years, mean ± SD)         48.5 ± 11.7        52.0 ± 10.2           51.3 ± 10.2      50.1 ± 10.5     0.052
  Histologic grade                                                                                         \<0.001
   I/II                          169 (56.7)         41 (75.9)             23 (37.0)        258 (79.1)       
   III                           129 (43.3)         13 (24.1)             39 (72.2)        68 (20.9)        
  Tumor stage                                                                                              0.017
   T1                            123 (41.3)         29 (53.7)             34 (54.8)        172 (52.8)       
   T2/T3                         175 (58.7)         25 (46.3)             28 (45.2)        154 (47.2)       
  Nodal stage                                                                                              0.457
   N0                            177 (59.3)         27 (50.0)             40 (64.5)        192 (58.9)       
   N1/N2/N3                      121 (40.6)         27 (50.0)             22 (35.5)        134 (41.1)       
  Estrogen receptor status                                                                                 \<0.001
   Negative                      152 (51.0)         15 (27.8)             39 (62.9)        80 (24.5)        
   Positive                      146 (49.0)         39 (72.2)             23 (37.1)        246 (75.5)       
  Progesterone receptor status                                                                             \<0.001
   Negative                      181 (60.7)         22 (40.7)             40 (64.5)        129 (39.6)       
   Positive                      117 (39.3)         32 (59.3)             22 (35.5)        197 (60.4)       
  HER2 status                                                                                              0.006
   Negative                      252 (84.6)         36 (66.7)             47 (75.8)        248 (76.1)       
   Positive                      46 (15.4)          18 (33.3)             15 (24.2)        78 (23.9)        
  Molecular subtype                                                                                        \<0.001
   Luminal A                     91 (30.5)          22 (40.7)             12 (19.4)        173 (53.1)       
   Luminal B                     58 (19.5)          18 (33.3)             13 (21.0)        77 (23.6)        
   HER2                          22 (7.4)           7 (13.0)              10 (16.1)        30 (9.2)         
   Triple-negative               127 (42.6)         7 (13.0)              27 (43.5)        46 (14.1)        
  ATP synthase in tumor                                                                                    0.178
   Negative                      8 (2.7)            1 (1.9)               2 (3.2)          19 (5.8)         
   Positive                      290 (97.3)         53 (98.1)             60 (96.8)        307 (94.2)       
  ATP synthase in stroma                                                                                   \<0.001
   Negative                      247 (82.9)         29 (53.7)             33 (53.2)        261 (80.1)       
   Positive                      51 (17.1)          25 (46.3)             29 (46.8)        65 (19.9)        
  Glutaminase in tumor                                                                                     0.512
   Negative                      84 (28.2)          13 (24.1)             17 (27.4)        105 (32.2)       
   Positive                      214 (71.8)         41 (75.9)             45 (72.6)        221 (67.8)       
  Glutaminase in stroma                                                                                    \<0.001
   Negative                      206 (69.1)         20 (37.0)             29 (46.8)        240 (73.6)       
   Positive                      92 (30.9)          34 (63.0)             33 (53.2)        86 (26.4)        
  Tumor mitochondrial status                                                                               0.217
   Dysfunctional                 94 (31.5)          20 (37.0)             26 (41.9)        96 (29.4)        
   Functional                    204 (68.5)         34 (63.0)             36 (58.1)        230 (70.6)       
  Stroma mitochondrial status                                                                              0.055
   Dysfunctional                 13 (4.4)           3 (5.6)               8 (12.9)         16 (4.9)         
   Functional                    285 (95.6)         51 (94.4)             54 (87.1)        310 (95.1)       
  Tumor autophagy status                                                                                   \<0.001
   Activated                     168 (56.4)         28 (51.9)             45 (72.6)        117 (35.9)       
   Nonactivated                  130 (43.6)         26 (48.1)             17 (27.4)        209 (64.1)       
  Stroma autophagy status                                                                                  \<0.001
   Activated                     9 (3.0)            11 (20.4)             13 (21.0)        21 (6.4)         
   Nonactivated                  289 (97.0)         43 (79.6)             49 (79.0)        305 (93.6)       
  MCT4 in tumor                                                                                            \<0.001
   Negative                      180 (60.4)         38 (70.4)             40 (64.5)        282 (86.5)       
   Positive                      118 (39.6)         16 (29.6)             22 (35.5)        44 (13.5)        
  MCT4 in stroma                                                                                           \<0.001
   Negative                      157 (52.7)         22 (40.7)             20 (32.3)        219 (67.2)       
   Positive                      141 (47.3)         32 (59.3)             42 (67.7)        107 (32.8)       
  Ki-67 LI (%, mean ± SD)        24.6 ± 22.5        13.2 ± 11.1           25.2 ± 18.6      11.5 ± 14.1     \<0.001
   Tumor recurrence              38 (12.8)          6 (11.1)              4 (6.5)          21 (6.4)        0.043
   Patient's death               36 (12.1)          5 (9.3)               6 (9.7)          20 (6.1)        0.081

^a^LI, labeling index; MCT4, monocarboxylate transporter 4.

![**Histologic and immunohistochemical features according to metabolic phenotypes of breast cancer.** The Warburg and mixed types show high histologic grade, estrogen receptor (ER) negativity and high Ki-67 labeling index (LI). In contrast, the reverse Warburg and null types show low histologic grade, ER positivity and low Ki-67 LI. ATP synthase and glutaminase were high in the reverse Warburg and mixed types and low in the Warburg and null types (*P* \< 0.001). BNIP3, BCL2/adenovirus E1B 19-kDa interacting protein 3; CAIX, carbonic anhydrase IX; GLUT1, glucose transporter 1; H & E, hematoxylin and eosin; MCT4, monocarboxylate transporter 4.](bcr3472-1){#F1}

Impact of metabolism-related proteins on patient prognosis
----------------------------------------------------------

The results of univariate analysis on the correlation between metabolism-related proteins and the clinicopathologic parameters of patients are summarized in Table  [7](#T7){ref-type="table"}. Shorter disease-free survival (DFS) was associated with Glut-1 positivity (*P* = 0.010), BNIP3 negativity, tumor phenotype (HER2 and TNBC; *P* \< 0.001) and tumor metabolic type (reverse Warburg type; *P* = 0.037) (Figure  [2](#F2){ref-type="fig"}). Shorter overall survival (OS) was associated with Glut-1 positivity (*P* = 0.023), tumor phenotype (HER2 and TNBC; *P* \< 0.001) and tumor metabolic type (mixed type; *P* = 0.045) (Figure  [2](#F2){ref-type="fig"}). Prognostic factors evaluated by multivariate Cox analysis included histologic grade, T stage, N stage, ER status, PR status, HER2 status, tumor phenotype, tumor metabolic phenotype and tumor expression of Glut-1. The results showed that the independent factors associated with shorter DFS were ER negativity (odds ratio (OR) = 2.7, 95% CI = 1.7 to 4.5; *P* \< 0.001), N stage (N0 vs. N1/2/3, OR = 2.3, 95% CI = 1.4 to 3.8; *P* = 0.001) and T stage (T1 vs. T2/3, OR = 2.4, 95% CI = 1.3 to 4.4; *P* = 0.002) and those associated with shorter OS were ER negativity (OR = 3.3, 95% CI = 2.0 to 5.5; *P* \< 0.001) and N stage (N0 vs. N1/2/3, OR = 2.3, 95% CI = 1.4 to 3.8; *P* = 0.001).

###### 

**Univariate analysis of the expression of metabolism-related proteins in breast cancers and disease-free survival or overall survival by logrank test**^**a**^

  **Immunohistochemical factors**   **Number of patients/ recurrence/death**   **Disease-free survival**   **Overall survival**                      
  --------------------------------- ------------------------------------------ --------------------------- ---------------------- ------------------ ---------
  Glut-1 in tumor                                                                                          0.010                                     0.023
   Negative                         504/37/37                                  128 (125 to 131)                                   131 (128 to 134)    
   Positive                         236/32/30                                  119 (112 to 126)                                   123 (118 to 128)    
  Glut-1 in stroma                                                                                         n/a                                       n/a
   Negative                         724/69/67                                  n/a                                                n/a                 
   Positive                         16/0/0                                     n/a                                                n/a                 
  CAIX in tumor                                                                                            0.740                                     0.222
   Negative                         520/49/45                                  126 (122 to 130)                                   130 (127 to 132)    
   Positive                         220/20/22                                  108 (102 to 113)                                   123 (117 to 130)    
  CAIX in stroma                                                                                           0.927                                     0.496
   Negative                         627/59/56                                  125 (122 to 129)                                   129 (126 to 132)    
   Positive                         113/10/11                                  103 (98 to 108)                                    116 (109 to 123)    
  ATP synthase in tumor                                                                                    0.506                                     0.936
   Negative                         30/4/3                                     102 (90 to 114)                                    129 (117 to 141)    
   Positive                         710/65/64                                  125 (122 to 129)                                   128 (126 to 131)    
  ATP synthase in stroma                                                                                   0.783                                     0.398
   Negative                         570/53/50                                  125 (121 to 129)                                   129 (126 to 132)    
   Positive                         170/16/17                                  118 (112 to 124)                                   122 (115 to 128)    
  Glutaminase in tumor                                                                                     0.323                                     0.164
   Negative                         219/24/25                                  123 (117 to 128)                                   126 (120 to 131)    
   Positive                         521/45/42                                  126 (122 to 130)                                   130 (127 to 133)    
  Glutaminase in stroma                                                                                    0.554                                     0.596
   Negative                         495/49/48                                  123 (119 to 128)                                   128 (125 to 131)    
   Positive                         245/20/19                                  127 (121 to 132)                                   128 (124 to 133)    
  BNIP3 in tumor                                                                                           0.004                                     0.426
   Negative                         504/59/50                                  123 (119 to 127)                                   128 (124 to 131)    
   Positive                         236/10/17                                  123 (119 to 127)                                   131 (126 to 135)    
  BNIP3 in stroma                                                                                          0.191                                     0.973
   Negative                         700/68/64                                  125 (121 to 128)                                   128 (126 to 131)    
   Positive                         40/1/3                                     116 (111 to 121)                                   121 (112 to 129)    
  MCT4 in tumor                                                                                            0.550                                     0.451
   Negative                         540/49/47                                  125 (121 to 129)                                   129 (126 to 132)    
   Positive                         200/20/20                                  116 (111 to 121)                                   126 (120 to 131)    
  MCT4 in stroma                                                                                           0.673                                     0.262
   Negative                         418/42/44                                  123 (118 to 127)                                   127 (123 to 131)    
   Positive                         322/27/23                                  128 (124 to 132)                                   130 (126 to 133)    
  Cytoplasmic beclin-1                                                                                     0.169                                     0.566
   Negative                         406/46/38                                  124 (119 to 128)                                   129 (126 to 132)    
   Positive                         334/23/29                                  121 (118 to 124)                                   126 (123 to 130)    
  Nuclear beclin-1                                                                                         0.157                                     0.031
   Negative                         666/66/66                                  125 (121 to 128)                                   128 (125 to 131)    
   Positive                         74/3/1                                     111 (106 to 115)                                   136 (132 to 139)    
  LC3A in tumor                                                                                            0.085                                     0.299
   Negative                         669/59/59                                  126 (122 to 129)                                   129 (126 to 132)    
   Positive                         71/10/8                                    113 (103 to 122)                                   124 (115 to 133)    
  LC3A in stroma                                                                                           0.801                                     0.541
   Negative                         687/65/64                                  125 (122 to 129)                                   128 (126 to 131)    
   Positive                         53/4/3                                     65 (62 to 68)                                      66 (64 to 68)       
  LC3B in tumor                                                                                            0.990                                     0.271
   Negative                         475/45/40                                  125 (121 to 130)                                   130 (127 to 133)    
   Positive                         265/24/27                                  118 (113 to 123)                                   125 (120 to 130)    
  LC3B in stroma                                                                                           0.481                                     0.565
   Negative                         688/66/64                                  125 (122 to 129)                                   128 (126 to 131)    
   Positive                         52/3/3                                     63 (60 to 66)                                      64 (62 to 66)       
  Cytoplasmic p62 in tumor                                                                                 0.958                                     0.528
   Negative                         274/26/23                                  121 (112 to 129)                                   129 (125 to 133)    
   Positive                         466/43/44                                  126 (122 to 130)                                   128 (125 to 131)    
  Nuclear p62 in tumor                                                                                     0.210                                     0.646
   Negative                         532/55/51                                  125 (122 to 129)                                   128 (125 to 131)    
   Positive                         208/14/16                                  117 (110 to 124)                                   128 (122 to 133)    
  Nuclear p62 in stroma                                                                                    0.720                                     0.387
   Negative                         512/48/45                                  126 (122 to 130)                                   129 (126 to 132)    
   Positive                         228/21/22                                  104 (99 to 109)                                    124 (118 to 130)    
  Tumor phenotype                                                                                          \<0.001                                   \<0.001
   Luminal A                        298/15/14                                  130 (126 to 133)                                   134 (131 to 137)    
   Luminal B                        166/12/11                                  129 (124 to 134)                                   130 (124 to 135)    
   HER2                             69/11/12                                   111 (100 to 121)                                   119 (108 to 130)    
   TNBC                             207/31/30                                  116 (109 to 124)                                   120 (114 to 126)    
  Metabolic status                                                                                         0.037                                     0.045
   Warburg type                     298/38/36                                  119 (112 to 126)                                   124 (119 to 128)    
   Reverse Warburg type             54/6/5                                     90 (83 to 96)                                      113 (106 to 121)    
   Mixed type                       62/4/6                                     105 (100 to 111)                                   112 (99 to 126)     
   Null type                        326/21/20                                  129 (126 to 133)                                   132 (129 to 136)    

^a^BNIP3, BCL2/adenovirus E1B 19-kDa interacting protein 3; CAIX, carbonic anhydrase IX; Glut-1, glucose transporter 1; LC3A, microtubule-associated protein 1 light chain 3α; LC3B, microtubule-associated protein 1 light chain 3β; MCT4, monocarboxylate transporter 4; n/a, not applicable; TNBC, triple-negative breast cancer.

![Disease-free survival (a) and overall survival curves (b) according to the metabolic phenotypes of breast cancer.](bcr3472-2){#F2}

Western blot analysis of metabolism-related proteins in tumor and stroma according to tumor phenotype
-----------------------------------------------------------------------------------------------------

Western blot analysis was performed to investigate expression of metabolism-related proteins in tumor and stroma according to the tumor phenotype. The expression of Glut-1 and ATP synthase was higher in HER2 and TNBC types, and the expression was higher in tumor than in stroma (Figure  [3](#F3){ref-type="fig"}). The expression of p62 was higher in tumor than stroma, regardless of the tumor phenotype.

![**Expression of metabolism-related proteins in tumor and stroma assessed by Western blot analysis according to tumor phenotype.** CAIX, carbonic anhydrase IX; GLS1, glutaminase 1; Glut-1, glucose transporter 1; LMA, luminal A; LMB, luminal B; LC3A, microtubule-associated protein 1 light chain 3α; MCT4, monocarboxylate transporter 4; S, stroma; T, tumor; TNBC, triple-negative breast cancer.](bcr3472-3){#F3}

Discussion
==========

In the present study, we investigated the differential expression of metabolism-related markers according to the subtypes of breast cancer. Expression of glycolysis markers such as Glut-1, CAIX and MCT-4 was highest in TNBC, which is consistent with the results of previous studies showing higher expression of Glut-1 and CAIX in basal-like breast cancer \[[@B19]\]. The active metabolic status of a tumor can be inferred from common histologic features of TNBC, such as high-grade nuclei, high-grade prominent necrosis and increased mitotic activity \[[@B20]\], and this was supported by the results of IHC in the present study. Tumor expression of Glut-1 was associated with higher histologic grade (*P* \< 0.001), ER negativity (*P* \< 0.001), higher T stage (*P* \< 0.001), and higher Ki-67 LI (*P* \< 0.001), whereas CAIX was associated with higher Ki-67 LI (*P* \< 0.001). Tumor expression of MCT4 was associated with higher histologic grade (*P* \< 0.001), ER negativity (*P* \< 0.001), PR negativity (*P* \< 0.001), higher T stage (*P* \< 0.001) and higher Ki-67 LI (*P* \< 0.001). In addition, expression of Glut-1, CAIX and MCT-4 was associated with factors reflecting higher metabolic status. In contrast, tumor expression of Glut-1, CAIX and MCT-4 was lowest in luminal A and B. Luminal type tumors tend to show a lower grade, lower mitotic index and less necrosis than the HER2 type or TNBC, suggesting nonactive metabolic status of the tumor, which was supported by the results of IHC.

The expression of Glut-1, CAIX, BNIP3, MCT4, LC3A, LC3B and p62 was observed not only in tumor cells but also in stromal cells, which has not been thoroughly described in previous studies. The reverse Warburg effect theory suggests that tumor stroma, along with the tumor *per se*, plays a role in cancer metabolism \[[@B2]-[@B5]\]. According to this theory, metabolism in stromal cells occurs through glycolysis due to dysfunctional mitochondria caused by increased autophagy, whereas metabolism of tumor cells occurs through OXPHOS in functional mitochondria. This contrasts with the conventional Warburg effect theory, which states that glycolysis is the major metabolic process in tumor cells. The major metabolic phenotypes in this study were the Warburg type (40.3%) and the null type (44.0%), according to the metabolic processes of tumor and stromal cells. We found that each metabolic phenotype investigated had different characteristics. The mixed type had higher histologic grade, ER negativity, PR negativity and higher Ki-67 LI, in contrast to the null type, which had lower histologic grade, ER positivity, PR positivity and Ki-67 LI (*P* \< 0.001). As both tumor cells and stromal cells are glycolytic in the mixed type and nonglycolytic in the null type, we speculate that the mixed type is a group of tumors with high metabolic activity and that the null type consists of tumors with lower metabolic activity. The results of the present study show that the mixed type had the highest percentage of activated autophagy, whereas the null type had the lowest percentage, thus supporting this hypothesis. In addition, different molecular subtypes of breast cancer were classified into different metabolic types. TNBC constituted the highest percentage of Warburg type and mixed type, whereas the luminal A type constituted the highest percentage of reverse Warburg type and null type (*P* \< 0.001). Moreover, the Warburg type and the mixed type were classified into groups with a higher Ki-67 LI, whereas the reverse Warburg type and the null type were classified into groups with a lower Ki-67 LI (*P* \< 0.001). This result is consistent with those of a former study on the reverse Warburg effect in which a luminal A breast cancer cell line, MCF-7, was used for *in vitro* study \[[@B6]\]. Thus, further *in vitro* studies should be carried out with various cell lines showing different molecular subtypes.

We identified the expression of a mitochondrial metabolism-related protein such as ATP synthase and glutaminase in the tumor and stroma in the present study. Notably, stromal expression of ATP synthase and glutaminase was high in the reverse Warburg type and mixed type and low in the Warburg type and null type (*P* \< 0.001). We speculate that stroma showing glycolysis have high mitochondrial metabolic activity, as both the reverse Warburg and mixed types are subtypes of the glycolysis type of stroma by definition. Because it has also been reported that certain types of tumor generate ATP through glycolysis as well as through mitochondrial OXPHOS, the hypothesis that dual types of stromal metabolism via the glycolysis pathway and the mitochondrial pathway should be investigated further.

The present study shows that the Warburg type and mixed type consisted of metabolically active and biologically aggressive tumors, whereas the reverse Warburg type and null type consisted of metabolically inactive and biologically nonaggressive tumors. This finding suggests that glycolysis of tumors significantly affects their metabolic and biological characteristics. The association of Glut-1 with shorter DFS and OS in univariate analysis supports this hypothesis.

A potential limitation of this study is the use of TMA cores for analysis, which may not truly represent the whole tumor. Although it is a reasonable contention, given the well-known intrinsic heterogeneity of breast cancer, this limitation was overcome by using two 3-mm tissue cores because it was previously reported that TMA with two 0.6-mm cores were representative of standard full tissue sections in breast cancer \[[@B21]\].

Among the breast cancer subtypes, TNBC comprised 28% of the total cases in this study, which is higher than the previously reported 12% to 24%. This difference can be attributed to possible differences in ethnic incidence, as reported previously, and to the overestimation of the true incidence potentially by the use of TMA containing part of the tumor, as we defined TNBC as all negative for ER, PR and HER2, which is similar to known phenomena of the discordance of ER, PR and HER2 expression between samples from core biopsy and excision \[[@B22]-[@B24]\]. Last, erroneous results of ER, PR and HER2 expression may affect the incidence, given that a 10% of false-negative rate and a 5% of false-positive rate were reported in ER expression, whereas a 4% of false-negative and false-positive cases were reported in HER2 \[[@B25]\]. Thus, cautious interpretation of the expression of those markers seems crucial, as misinterpretation of results may lead to the misclassification of the molecular subtypes.

Conclusion
==========

Breast cancer is heterogeneous in its metabolic status, and therefore it can be classified into various metabolic phenotypes. Specifically, the Warburg and mixed types had strong associations with TNBC, whereas the reverse Warburg type and the null type were associated with the luminal type, suggesting a correlation between metabolic phenotype and the biology of breast cancer.
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